Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2009Gut

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCynthia H. SeowUniversity of CalgaryANAlvin NewmanUniversity Hospitals Sussex NHS Foundation TrustSISue P. Irwin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Seow et al. (2009) studied this question.

synapsesocial.com/papers/6a72a8d25d37378ac1df583ahttps://doi.org/10.1136/gut.2009.183095
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study)2006 · 273 citations
  2. 2Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis2008 · 106 citations
  3. 3Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis2005 · 3,926 citations
  4. 4Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease2003 · 2,029 citations